Lecigon

Entacapone, Levodopa and Carbidopa, the active ingredients in Lecigon, are a combination of a MAO‑B inhibitor and a DOPA decarboxylase inhibitor presented as an oral tablet for intestinal use. It is indicated for the management of Parkinson's disease in adults. GNH USA supplies Lecigon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecigon is a combination antiparkinson agent that targets motor symptoms and fluctuations in Parkinson's disease. - Parkinson's disease (early stage): improves motor function and reduces rigidity. - Parkinson's disease with motor fluctuations: decreases "off" periods and prolongs levodopa effect. - Advanced Parkinson's disease: enhances overall symptom control and supports daily activities.

Lecigon may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dyskinesia: involuntary movements, especially at higher doses. - Orthostatic hypotension: dizziness upon standing. - Headache: transient cranial discomfort.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes, requires immediate medical attention. - Neuroleptic malignant syndrome: high fever, muscle rigidity, life‑threatening. - Anaphylaxis: sudden allergic reaction with rash, swelling, breathing difficulty.

Before initiating Lecigon, clinicians should consider several safety measures. - Monitor for dyskinesia: adjust dose if involuntary movements appear. - Assess liver function: periodic tests are recommended due to potential hepatotoxicity. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal effects. - Use caution in cardiovascular disease: orthostatic hypotension may exacerbate existing conditions. - Contraindicated in known hypersensitivity to any component. - Store at room temperature: keep in the original pack, protect from moisture and direct sunlight.

Lecigon can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Certain antihypertensives (e.g., alpha‑blockers): may cause severe hypotension. - Anticholinergic agents: can intensify central side effects.

Moderate Interactions (Monitor Closely): - SSRIs and other serotonergic drugs: monitor for serotonin syndrome. - Iron or dietary supplements: may reduce levodopa absorption; separate dosing by at least 2 hours. - Other Parkinson’s medications (e.g., dopamine agonists): dose adjustments may be needed.